Because HER2-positivity in HR+ breast cancer is associated with ET resistance, potentially due to the crosstalk mechanism(s), including attenuation of ER and PR expression8, hormone sensitivity may theoretically be restored through HER2 blockade111. This evidence concerns the gene ESR1 and breast carcinoma.